CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions |
12 Months Ended | |||||
---|---|---|---|---|---|---|
Mar. 15, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|||
Allocated share-based compensation expense | $ 338.0 | $ 330.7 | $ 287.1 | |||
Income tax benefit, release of deferred tax asset valuation allowance | 420.2 | 38.1 | ||||
Corporate Headquarters Lease | ||||||
Gain on partial operating lease termination | 158.8 | 13.6 | ||||
Cost of revenue | ||||||
Allocated share-based compensation expense | 23.3 | 24.7 | 23.2 | |||
Research and development | ||||||
Allocated share-based compensation expense | [1] | 237.6 | 232.3 | 190.1 | ||
Research and development | President | ||||||
Allocated share-based compensation expense | $ (6.7) | 4.4 | ||||
Sales and marketing | ||||||
Allocated share-based compensation expense | 22.0 | 22.4 | 25.0 | |||
General and administrative | ||||||
Allocated share-based compensation expense | $ 55.1 | $ 51.3 | $ 48.8 | |||
|